IBC-Oxford University2023_BJSOral_4Comparison Between Two Different Intragastric Balloon Intervention in Terms of Weight- Loss, Tolerance, and Complications

Abstract

Abstract Introduction Obesity and its complications have been rising worldwide. Several interventions are available including lifestyle intervention, drug therapy, devices such as intragastric balloon (IGB), and metabolic surgery. This study focuses on two intragastric balloon (IGB) -The Orbera365 and Elipse in terms of weight loss, tolerance, and complications. Methods We performed a retrospective before and after study on patients who underwent IGB intervention in the period between July 2020–November 2021. Data on weight loss, tolerance and complications were recorded from patient’s files. Results A total of 311 patients underwent Elipse intervention and 107 underwent Orbera365 intervention. The average weight and BMI prior to Elipse were 94.7±19.1 kgs and 35.2±5.5 kg/m2 and Orbera365 was 94.6±19.1 kgs and 35.4±3.9 kg/m2. The average weight and BMI decreased significantly in four months post-Elipse and was 83.7±17.4 kgs and 31.3±4.8 kg/m2 while in 12-months post Orbera365, it was 79.8±15.5 kgs and 30.1±4.1 kg/m2. Moreover, maximum weight loss is achieved in the 4-6 months of balloon intervention, which continues at reduced rate till the end of the term. Intolerance rate was higher in Orbera365 (6.5%) as compared to Elipse (2.6 %). Conclusion IGB is effective in terms of weight reduction for short term with acceptable rate of complications and intolerance, however weight regain is observed after IGB removal.